13F data as of 2024-12-31 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

CUSIP

09075P105

FAQ

Who are the top institutional investors holding BIOXCEL THERAPEUTICS INC (BTAIEUR)?

Major stakeholders currently include Armistice Capital, LLC ($1.6M), UBS Group AG ($477.6K), Vanguard Group INC ($444.1K). Based on the latest 13F filings, there are a total of 51 tracked investment funds and institutions maintaining positions in BTAIEUR.

What is the overall institutional sentiment toward BTAIEUR recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $1.4M, driven by 5 managers accumulating shares while 6 reduced their exposure.

Which institutions have been selling or reducing their BTAIEUR positions?

In the latest period, 6 funds trimmed their holdings, and 0 managers completely exited their positions. The aggregate reported sell value was $115.8K.

Are there any notable investors adding BTAIEUR to their portfolios?

Yes, buying activity remains notable. 3 institutions opened new positions in {ticker}, and 2 existing holders added to their shares. The total reported buy value for the quarter amounted to $1.7M.